NCT03746522: A trial that was reported late by Rhythm Pharmaceuticals, Inc.
This trial has reported, although it was 548 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03746522 |
|---|---|
| Title | A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 23, 2018 |
| Completion date | Nov. 16, 2020 |
| Required reporting date | Nov. 16, 2021, midnight |
| Actual reporting date | May 18, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 23, 2025 |
| Days late | 548 |